Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

KIN1408

🥰Excellent
Catalog No. T15662Cas No. 1903800-11-2
Alias KIN 1408

KIN1408 is an antiviral small molecule compound that is an agonist of the RIG-1-like receptor (RLR) pathway and is able to drive the activation of IRF3 (Interferon Regulatory Factor 3) to induce the expression of innate immunity genes (e.g., MDA5, RIG-1, Mx1, IRF7, and IFIT1), and to promote the nuclear translocation of IRF3 by targeting MAVS (Mitochondrial Antiviral Signaling Protein) or its upstream IRF3 nuclear translocation by targeting MAVS (mitochondrial antiviral signaling protein) or its upstream factors. KIN1400 is the parent, and KIN1409 is a derivative.

KIN1408

KIN1408

🥰Excellent
Purity: 98.61%
Catalog No. T15662Alias KIN 1408Cas No. 1903800-11-2
KIN1408 is an antiviral small molecule compound that is an agonist of the RIG-1-like receptor (RLR) pathway and is able to drive the activation of IRF3 (Interferon Regulatory Factor 3) to induce the expression of innate immunity genes (e.g., MDA5, RIG-1, Mx1, IRF7, and IFIT1), and to promote the nuclear translocation of IRF3 by targeting MAVS (Mitochondrial Antiviral Signaling Protein) or its upstream IRF3 nuclear translocation by targeting MAVS (mitochondrial antiviral signaling protein) or its upstream factors. KIN1400 is the parent, and KIN1409 is a derivative.
Pack SizePriceAvailabilityQuantity
2 mg$46 In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Purity:98.61%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
KIN1408 is an antiviral small molecule compound that is an agonist of the RIG-1-like receptor (RLR) pathway and is able to drive the activation of IRF3 (Interferon Regulatory Factor 3) to induce the expression of innate immunity genes (e.g., MDA5, RIG-1, Mx1, IRF7, and IFIT1), and to promote the nuclear translocation of IRF3 by targeting MAVS (Mitochondrial Antiviral Signaling Protein) or its upstream IRF3 nuclear translocation by targeting MAVS (mitochondrial antiviral signaling protein) or its upstream factors. KIN1400 is the parent, and KIN1409 is a derivative.
In vitro
KIN1408 exhibits activity against HCV, influenza A, Ebola, Nipah, and Lassa viruses. KIN1408 also has the ability to drive IRF3 activation to induce the expression of innate immune genes (MDA5, RIG-1, Mx1, IRF7, and IFIT1 in THP-1 cells) and simultaneously inhibit dengue virus 2 RNA levels. [1-2]
In vivo
Methods: MOLP-8 tumor model mice were treated with AZD-5991 (10-100 mg/kg, intravenous injection) and the efficacy of AZD-5991 on MOLP-8 tumor growth in vivo was evaluated.
Results: AZD-5991 produced dose-dependent antitumor effects ranging from tumor growth inhibition (TGI) to tumor regression (TR). After ten days of treatment, AZD-5991 showed a TGI of 52% and 93% at 10 and 30 mg/kg, respectively (p < 0.0001). [1]
AliasKIN 1408
Chemical Properties
Molecular Weight479.5
FormulaC25H19F2N3O3S
Cas No.1903800-11-2
Relative Density.1.430 g/cm3 (Predicted)
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 30 mg/mL (62.57 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.0855 mL10.4275 mL20.8551 mL104.2753 mL
5 mM0.4171 mL2.0855 mL4.1710 mL20.8551 mL
10 mM0.2086 mL1.0428 mL2.0855 mL10.4275 mL
20 mM0.1043 mL0.5214 mL1.0428 mL5.2138 mL
50 mM0.0417 mL0.2086 mL0.4171 mL2.0855 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy KIN1408 | purchase KIN1408 | KIN1408 cost | order KIN1408 | KIN1408 chemical structure | KIN1408 in vivo | KIN1408 in vitro | KIN1408 formula | KIN1408 molecular weight